The global CBD size is projected to continue its seemingly ever-accelerating growth and is expected to reach USD 23.6 billion, expanding at a CAGR of 22.2%, according to a new study by Grand View Research, Inc. Increasing adoption of cannabidiol (CBD) infused products in various industries such as pharmaceuticals, personal care and cosmetics, and nutraceuticals along with its medical applications is expected to drive the market over the forecast period. The availability of marijuana-derived CBD products in dispensaries, as well as government-approved pharmacies and stores and high efficacy of marijuana-derived CBD compared to hemp-derived CBD, are some of the pivotal factors for the growth of the segment according to Grand View. Ease of availability of a wide range of CBD based products to the consumers is one of the key factors driving the growth of this segment. Furthermore, increasing the adoption of cannabidiol infused pharmaceuticals for various conditions such as chronic pain, epilepsy, autism, and anxiety is anticipated to support the growth of this segment over the forecast period.
The rising Awareness of the health benefits of CBD infused products is expected to grow the market for years to come, according to several industry reports. CBD infused products offer wide-ranging health benefits with few side effects and low risk of addiction. Recently, CBD drinks are increasing in both popularity and availability as cannabis products and marijuana has become legalized in states across the country. CBD to consumable products may make it easier for consumers to incorporate it into their lifestyles and gain these benefits. Currently, cannabis-based concentrates, extracts, and edibles are becoming highly popular among consumers. It is expected that U.S. consumer sales of CBD will reach around $1.8 billion U.S. dollars by 2022. However, regulation and compliance on the use of CBD in the food and beverage industry have the potential to hampers the growth of the market. The market is expected to exhibit significant growth in the forecast period due to rising adoption of natural products over pharmaceutical products is an opportunity for this market.
Puration, Inc. (OTCPK: PURA) BREAKING NEWS: PURA Makes Bid For Hemp4mula CBD Confections Backed By $5 Million Investment - Puration today announced making a formal proposal to Kali-Extracts (KALY) to acquire KALY's Hemp4mula CBD Infused Confections operation. On Monday, earlier this week, PURA announced closing on a $5 million investment to fund the prospective acquisition of cannabis-infused beverage, edible and topical operations. The $5 million investment is structured as a debt facility whereby funds can be drawn as needed to fund acquisitions. The drawn funds would be secured by the acquired asset and the debt can be repaid in stock at $0.10 per share. Hemp4mula is the first target acquisition for PURA in an anticipated series of acquisitions.
Hemp4mula currently includes two products, Hemp4mula Gummies and Hemp4mula Gum each infused with 10mg of CBD extracted from hemp.
Read this and more news for PURA at https://www.financialnewsmedia.com/news-pura/
Read More at Source: PR NewsWire